Background-Evidence
V ena cava filters (VCFs) are frequently deployed in patients who are hospitalized for acute venous thromboembolism (VTE). If anticoagulant treatment cannot be given, placement of a VCF may be the only treatment option available to reduce the risk of pulmonary embolism (PE) or dying of fatal PE. However, there is no strong evidence that use of a VCF prevents either death or further PE. [1] [2] [3] Instead, observational studies of VTE patients treated with a VCF in conjunction with anticoagulant therapy have reported numerous thrombotic and embolic complications. [4] [5] [6] [7] [8] [9] 
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In a study of VCF use in California hospitals, 10 we observed wide variation in the use of VCFs, from 0% to 40%, among patients admitted to different hospitals with a principal diagnosis of VTE, even after adjusting for important clinical parameters. These findings suggest that patients with similar clinical characteristics are being treated or not treated with a VCF largely on the basis of the prevalent practice pattern at their hospital.
In 2 relatively small, randomized, clinical trials, VCF use was studied in patients with acute deep vein thrombosis (DVT) 3 and acute PE 11 who also received standard anticoagulation therapy. VCF use provided no significant survival benefit and did not reduce the frequency of subsequent PE in patients who presented with PE. 11 In the study of patients who presented with acute DVT (randomized to a permanent or no VCF), the incidence of PE was decreased in patients randomized to VCF use, but recurrent VTE manifested as acute DVT was increased.
acute VTE who have a contraindication to anticoagulation such as recent or planned major surgery or active bleeding. Conducting a randomized study of VCF use in patients with a contraindication to anticoagulation would be exceptionally difficult because most clinicians would feel compelled to insert a VCF if they were unable to administer anticoagulant treatment. However, it is possible to use administrative health data to identify patients with acute VTE patients who have a contraindication to anticoagulation and to determine the effect of VCF use by propensity score methodology to analyze important outcomes such as mortality and recurrent VTE.
The aim of this study was to use a large observational data set to analyze the effectiveness of VCF use in patients hospitalized for acute VTE who either had or did not have a contraindication to anticoagulation therapy. The principal outcomes of interest were death within 30 or 90 days of admission and recurrent VTE manifested as either PE or DVT within 1 year of hospital discharge. We hypothesized that VCF use would have no effect on short-term survival but would increase the incidence of recurrent VTE manifested as DVT.
Methods

Study Design
This was a retrospective study using observational data. We determined the incidence of death or recurrent VTE among adults without active cancer who were admitted to a nonfederal California hospital for acute VTE during a 6-year period from 2005 through 2010 and who either received or did not receive a VCF during the index hospitalization. We stratified the study population by the presence or absence of a contraindication to anticoagulation therapy.
Database
The study was conducted using the California Patient Discharge Database (PDD) linked with the California emergency department (ED) and master death file databases. 12 These data are collected and maintained by the California Office of Statewide Planning and Design. The PDD contains administrative hospital discharge data, as required (and audited) by the Centers for Medicare & Medicaid Services. The database includes demographic information, a principal diagnosis for the hospitalization and up to 25 additional clinical diagnoses, and a list of up to 20 major procedures performed on every patient hospitalized in all nonfederal acute care hospitals in California (the PDD includes 95%-97% of all discharges in the state). The ED records include similar data for patients evaluated at but not admitted to all hospital-affiliated EDs. Serial hospital/ ED records can be linked with the use of an encrypted form of the Social Security number called the record linkage number that is generated by California Office of Statewide Planning and Design for the 95% of patients who have a Social Security number. The PDD and ED data sets do not list the medications prescribed to the patient. Codes for the administration of parenteral anticoagulation exist but are not reliable because there is no information about intensity of anticoagulation therapy, duration of therapy, or overall adequacy of anticoagulation therapy. VTE events diagnosed and treated in the outpatient arena are not include in either the PDD or ED databases.
Medical diagnoses and major procedures (with date performed) are coded with International Classification of Diseases, Ninth Revision, Clinically Modified (ICD-9-CM). Since 1996, all medical diagnoses in the PDD require a present-on-admission (POA) Figure 1 shows a schematic flow diagram of the criteria applied to assemble the study populations. We identified all patients ≥18 years of age who had a record linkage number. Patients were excluded if they had a VCF previously placed back to July 1, 1991, or if there was a diagnosis of active cancer (code 140.0-209.9, except for nonmelanoma skin cancer, 173.0-173.9) either at the time of the index 
Study Population
Acute VTE
Patients admitted for acute VTE were identified by the presence of a specific principal diagnosis code (see Table I in the online-only Data Supplement) for either PE or lower-extremity DVT. For each linked record, only the first hospitalization for acute VTE was analyzed. Patients coded as having both DVT and PE were classified as having a PE. ICD-9-CM codes for a principal diagnosis of acute lowerextremity DVT or acute PE have been validated and shown to have a positive predictive value of ≈95%.
14 The POA indicator has also been validated. 15 
VCF Use
VCF placement was identified by the presence of the ICD-9-CM code 38.7 (interruption of the vena cava). VCF removal is ICD-9-CM code 39.99 or Current Procedural Terminology code 037203, but these codes were encountered so infrequently (314 of 9346 patients, 3.4%) that retrieval was not incorporated into any analysis. 16 
Active Bleeding
To isolate the patients who were likely not to have received anticoagulation during all or part of the hospital stay, we identified all patients with active bleeding, which was ascertained with specific ICD-9-CM codes (Table II in the online-only Data Supplement) that have been validated in other studies. 17, 18 The bleeding was classified as intracranial, gastrointestinal, or other. Hematuria and epistaxis were included as other bleed only if there was coding for ≥1 blood transfusions (codes 99.00, 99.03, 99.04-99.07). Bleeding events were categorized as being POA=Y/W or POA=N/U on the basis of the POA indicator code, which accompanies each ICD-9-CM diagnosis codes.
Surgery
To isolate another subgroup of patients who were likely to have had anticoagulation withheld during all or part of the hospital stay, we identified patients who underwent a major surgical operation during the hospital stay. Major diagnostic or therapeutic operating room procedures were defined with the use of a modification of the Centers for Medicare & Medicaid Services reference codes, 19 specifically excluding VCF insertion (code 38.7) as a surgical procedure. Vascular procedures for venous thrombectomy or procedures used in conjunction with thrombolysis were not included in the definition of major surgery (Table III in 
Outcomes
Principal outcomes were death within 30 and 90 days, recurrent VTE manifested as PE (with or without DVT), or DVT alone within 1 year of hospital discharge. A recurrent VTE event after the index admission was defined by a hospital readmission or an ED visit with a principal diagnosis of acute DVT or PE or by a diagnosis of acute VTE during a subsequent hospitalization (POA=N) that was within the specified follow-up time period.
Covariates
Covariates included demographic variables, comorbidities, previous surgery, severity of illness, PE versus DVT, use of thrombolysis on day 1 to 2, and bleeding present on admission. Preexisting comorbid conditions (n=23) were defined with the Elixhauser comorbidity software. 20, 21 Proprietary software from 3M (all patient refined-diagnosis-related group grouper, version 24) was applied to every record to generate a severity of illness level and a risk of mortality level at the time of admission. 22, 23 Software categorized each of these parameters as mild, moderate, major, or extreme. Hospital characteristics were specified on the basis of size (<100, 101-200, >200 beds), type (private, Kaiser affiliated, academic), location (rural or urban), and kind (profit, not for profit).
Analytic and Statistical Methodology
All patients were classified into 1 of 3 mutually exclusive groups: Patients in group 1 had neither of the 2 identifiable contraindications to anticoagulant treatment; patients in group 2 had a transient contraindication to anticoagulant therapy because they underwent a major operating room procedure, with or without active bleeding, during the index hospitalization or within 3 days before admission; and those in group 3 had a transient or permanent contraindication to anticoagulant therapy because they had active bleeding either present on admission or arising during the hospitalization. In the absence of any reliable data (coding) to define ongoing therapeutic anticoagulation, this grouping allowed us to distinguish patients who likely received therapeutic anticoagulation for treatment of the acute VTE from patients who probably received delayed, interrupted, inadequate, or no anticoagulation treatment.
Propensity Score
A logistic regression model was used to estimate each patient's propensity of having a VCF inserted on the basis of factors likely associated with VCF use, 10 including hospital variables (type, location, size), demographic variables (age, sex, race/ethnicity), and clinical variables (eg, PE, proximal DVT, distal DVT alone, comorbid conditions, severity of illness). Hospital-specific fixed effects were used to proxy for unobserved patient characteristics that may differ across hospitals. Outcomes were compared by use of models that used either inverse probability of treatment weighting or matching based on the propensity score using the calipers method, with the caliper equal to 0.001. 24 The effect of propensity score adjustment on the standardized mean differences in baseline covariates between the patients who received or did not receive a VCF was determined for each subgroup. 25 
Immortal Time Bias
Because the day of VCF insertion can vary from early to late during the index hospitalization, analysis of the effect of VCF use is subject to immortal time bias. [26] [27] [28] Patients who did not receive a VCF might have died before a VCF could be inserted, whereas all of the VCFtreated patients were alive when the VCF was inserted (hence they were "immortal" during the interval from the date of admission to the date of insertion). To account for this bias, VCF use was entered as a time-dependent covariate in the inverse probability-weighted proportional hazard models for death. 25 In propensity-matched analyses, patients not treated with a VCF had to be alive on the hospital day when the matched VCF case had the filter inserted. 28 Outcomes were modeled with proportional hazard methodology after testing for the proportionality assumption. For patients in groups 1 and 3, death was analyzed at with 30 and 90 days from the day of admission, whereas for group 2, death was analyzed from the day of surgery. The demographic and clinical risk factors used for adjustment in the models for death (and recurrent VTE) in each group are shown on Forest plots (Figures 2-4) and included bleeding subtypes, PE (versus DVT), and risk of mortality.
Categorical data were analyzed with χ 2 testing. Analyses were performed with SAS version 9.3, and a 2-sided value of P<0.05 was considered statistically significant. All models were tested for proportionality with log-negative log plots.
Results
The clinical characteristics of the patients in each subgroup are shown in Table 1 . Across all 3 subgroups, patients treated with a VCF were older, had more chronic comorbidity, had a higher frequency of proximal DVT, and had greater severity of illness and risk of mortality at the time of admission. Figure 5 shows the standardized mean differences of these parameters in each group before and after adjustment for propensity score with inverse probability weighting. As shown in this figure, the inverse probability of treatment weighting made the characteristics of the VCF and no-VCF groups more balanced compared with the observed differences.
A VCF was placed in 7762 of the 80 697 patients (9.6%) who had no contraindication to anticoagulation, in 489 of the 1445 patients (33.8%) who underwent a major operating room procedure, and in 1095 of the 3017 patients (36.2%) who had active bleeding. Overall, 19.4% of the VCFs were inserted on hospital day 1, 29.2% on day 2, 17.8% on day 3, and 11.1% on day 4, with 22.5% inserted after this day.
The effect of VCF use on the principal outcomes is summarized in Table 2 . As shown in Figure 2 , use of a VCF did not significantly improve survival among the group 1 patients, who had no contraindication to anticoagulation. The unadjusted 30-day mortality rate was 4.5% in the VCF patients and 3.3% in the no-VCF patients. With the use of inverse probability weighting and adjustment for immortal time bias, the risk of death within 30 days was not significantly higher among VCF-treated patients (hazard ratio [HR], 1.12; 95% confidence interval [CI], 0.98-1.28). There was no interaction between VCF use and a diagnosis of PE versus DVT (P>0.5). Similar findings were noted with the use of matching methodology. The unadjusted incidence of PE within 1 year was 2.8% among VCF patients and 3.2% among no-VCF patients. There was no difference in the risk of recurrent PE within 1 year after discharge in the adjusted model (HR, 1.05; 95% CI, 0.89-1.24). The incidence of DVT within 1 year was 5.4% among VCF patients and 3.7% among no-VCF patients. The adjusted risk of recurrent DVT within 1 year was significantly higher among VCF-treated patients than among no-VCF patients (HR, 1.53; 95% CI, 1.34-1.74).
Among the group 2 patients who underwent surgery, VCF use did not affect the 30-day risk of death (HR, 1.12; 95% CI, 0.71-1.77), 1-year risk of recurrent PE (HR, 0.85; 95% CI, 0.35-2.10), or 1-year risk of recurrent DVT (HR, 1.15; 95% CI, 0.57-2.32).
Among group 3 patients, all of whom had active bleeding, VCF use was associated with a crude 30-day mortality of 9.5% among VCF patients and 11.5% among no-VCF patients. There was a statistically significant 32% reduction in the adjusted risk of death within 30 days after inverse probability weighting of the propensity and adjustment for immortal time bias (HR, 0.68; 95% CI, 0.52-0.88). The Forest plot is shown in Figure 3 . Similarly, using propensity matching and adjusting for immortal time bias reduced the risk of death associated with VCF use by 39% (HR, 0.61; 95% CI, 0.39-0.95). Proportional hazard models for death within 90 days after admission showed that VCF use remained associated with a similar significant reduction in the risk of death (HR, 0.73; 95% CI, 0.59-0.90). The distribution of the day of death among the patients who received or did not receive a VCF is shown in Figure 6 , which demonstrates that the majority of deaths in the first 8 days occurred in patients who did not receive a VCF, making adjustment for immortal time bias mandatory.
In the group 3 patients, who had active bleeding, the crude incidence of PE within 1 year was 2.6% for VCF patients and 2.6% among the no-VCF patients, and there was no significant reduction in the adjusted risk of recurrent PE within 1 year (HR, 1.04; 95% CI, 0.67-1.61). Performing a sensitivity analysis to include recurrent PE events coded as occurring during the index hospitalization (POA=N/U) did not change the results. In this group, the crude incidence of recurrent DVT within 1 year in the VCF patients was 6.1% compared with 2.5% in the no-VCF patients, and in the adjusted risk model, recurrent DVT within 1 year was significantly higher among VCF patients (HR, 2.35; 95% CI, 1.56-3.52).
Among the 1095 patients with active bleeding who received a VCF, 104 (9.5%) died within 30 days compared with 221 deaths in the 1922 patients (11.5%) who did not receive a VCF. Twenty-four of the 104 VCF-treated patients (23.1%) who died had VTE listed as the cause of death, and 8 of these VTE deaths (33%) had a death certificate diagnosis of PE (International Classification of Diseases, 10th Revision code I26.9). In comparison, 57 of the deaths (25.8%) among the patients not treated with a VCF had VTE listed as the cause of death, and 38 of these VTE deaths (66%) had a death certificate diagnosis of PE.
Discussion
The principal findings of this study were that VCF use did not prevent either death or recurrent VTE manifested as PE in patients with acute VTE who had no contraindication to anticoagulation, but VCF use did reduce the 30-and 90-day risk of death by ≈30% in patients with active bleeding who likely had anticoagulation therapy withheld either at the time of admission or during the index hospitalization. The finding that the lower risk of death persisted to 90 days after admission suggests that VCF use did not simply delay the time of death. These findings are consistent with the recently published findings from the Prevention of Recurrent Pulmonary Embolism by Vena Cava Interruption 2 (PREPIC 2) clinical trial study, 11 which reported that VCF use had no effect on morality or recurrent PE among patients who presented with PE who had no contraindication to anticoagulant therapy. Our findings support the recent 2016 American Society of Chest Physician guidelines 29 that recommend that a VCF be used for early treatment only in patients with an acute proximal lower-extremity DVT or PE who cannot receive anticoagulant therapy.
The rather striking reduction in short-term mortality associated with VCF use among the patients with acute VTE who had active bleeding was not expected. In an analysis of a small number of patients in a European VTE registry who were at increased risk for bleeding during anticoagulation, 30 VCF use was not associated with a significant reduction in death within 30 days. This study reported that VCF use was associated with a significant reduction in death attributed to PE, but no adjustment was made for immortal time bias. 31 Similarly, several retrospective studies have reported a beneficial effect of VCF use on mortality in highly specified subgroups of patients with acute VTE who were at high risk for dying, but again, none of these studies used rigorous methodology to account for immortal time bias. 30, [32] [33] [34] A possible explanation for the observed reduction of mortality associated with VCF use in acute VTE patients who had active bleeding is treatment bias, that is, the ordering of insertion of a VCF preferentially in less ill patients. However, the overall severity of illness and risk of mortality at the time of admission were significantly higher among patients treated with a VCF compared with the patients who did not receive a VCF. At the time of admission, 46.8% of the patients with major bleeding who had a VCF placed were classified as having major or extreme risk of mortality compared with only 31.3% of the patients with major bleeding who did not receive a VCF. In fact, severity of illness and risk of mortality were significantly higher among the patients who had a VCF inserted in each of the 3 groups analyzed. Moreover, in the models for death, we adjusted for important risk factors for death, including age, race, insurance status, and the number of comorbidities, in addition to the risk of mortality.
Although the patients with acute VTE who required major surgery likely had anticoagulation discontinued, at least transiently, during the perioperative period, use of a VCF had no effect on the risk of death within 30 or 90 days. We had no direct measure of the duration or intensity of anticoagulant therapy, but we suspect that patients who underwent an unrelated major procedure during their hospitalization for VTE were probably highly selected, and these patients likely had therapeutic anticoagulation withheld for a relatively brief period. In contrast, patients with active bleeding were not selected (ie, most of these events were probably unexpected complications of initial VTE therapy) and probably had a longer mean duration without receiving anticoagulation.
The finding that VCF use reduced the short-term risk of death among patients with active bleeding but had no longterm effect on the risk of recurrent PE may seem contradictory. If a VCF provides a physical barrier that prevents or retards the migration of embolus into the lungs, then VCF use should theoretically prevent both early deaths and symptomatic PEs, at least until the time of VCF retrieval. Several factors may explain this paradox. First, many patients with active bleeding probably had anticoagulation therapy restarted as soon as the risk of further bleeding was deemed to be sufficiently low. Second, a modest proportion of the VCFs might have been removed within a few weeks of insertion. 16 Third, VCF use might have improved survival not by catching large clots that embolized toward the lung but by breaking up these embolizing thrombi into smaller pieces that were better tolerated hemodynamically. Although causes of death on death certificates are often not accurate, 35 we found that in the patients with active bleeding who died in the hospital, the proportion of deaths attributed to PE was higher in those who did not receive a VCF compared with those who had a VCF inserted. However, this finding could be attributable to attribution bias because physicians may be less likely to blame a death on PE knowing that a VCF had been inserted.
It is unlikely that a clinical trial will ever be conducted to assess the efficacy of VCF use among patients with a clear contraindication to anticoagulation therapy because of active bleeding. Such patients are relatively uncommon; they are quite ill; and the need to obtain prompt informed consent would make conducting such a study extremely challenging. The present retrospective analysis represents an attempt to determine whether VCF use may be beneficial among patients who have at least a temporary contraindication to anticoagulation.
To minimize sources of bias inherent in retrospective observational studies, we used propensity score analytical methods to balance the distribution of all observed baseline characteristics, 24 and we adjusted for immortal time bias. [26] [27] [28] Immortal time bias arises in observational studies when patients who appear to be eligible for an intervention such as VCF insertion die before they can receive the intervention, yet they are included in the analysis and categorized as not receiving the intervention. Accepted methods of circumventing this bias to ensure a fair comparison of VCF use and nonuse were incorporated into our analysis. 26, 28 In our analysis of the patients who had a contraindication to anticoagulation because of active bleeding, the reduction in the risk of dying associated with VCF use fell from 53% to 32% after accounting for immortal time bias.
Limitations of this analysis include the absence of any information about the use, intensity, or duration of anticoagulation therapy. Except for patients with active bleeding and those who underwent major surgery, we assumed that anticoagulation therapy was administered to all patients. Active bleeding is likely an excellent surrogate for avoidance of anticoagulation. To the extent that patients classified as having major bleeding actually had only minor bleeding and were either maintained on anticoagulation or taken off for only a short period of time, our findings may have underestimated the true effect of VCF use on mortality among VTE patients who did not receive anticoagulation therapy. Because <5% of the VCF-treated patients had a procedure code for VCF removal, we did not adjust for removal. The findings of this study do not apply to patients with cancer, who were excluded because of the difficulty of adjusting for their short-term risk of death. Finally, our database did not allow us to identify any patients who had recurrent DVT diagnosed and treated only in the outpatient arena. However, because the proportion of patients diagnosed with recurrent DVT in the outpatient setting was likely similar among patients treated and not treated with a VCF, the results of our proportional hazard modeling are likely unaffected.
Conclusions
The findings of this retrospective analysis of observational data suggest that VCF use reduced the short-term risk of death among VTE patients without cancer who had a temporary contraindication to anticoagulation owing to active bleeding. This lower risk of death was not observed among patients who had no contraindication to anticoagulation treatment, and it was not observed in patients who had a temporary contraindication to anticoagulation because they underwent major surgery. Among patients with or without a contraindication to anticoagulation, insertion of a VCF was associated with a higher risk of being diagnosed with acute DVT within 1 year, but filter use was not associated with a reduction in the risk of recurrent PE within 1 year.
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